SCHEMBL574252

SCHEMBL574252

N#Cc1ccc2sccc2c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.49
SLC6A4 P31645 1/20 0.49
SLC6A3 Q01959 1/20 0.49
CYP2A6 P11509 3/20 0.46
DYRK1A Q13627 1/20 0.42
IMPDH2 P12268 1/20 0.41
IMPDH1 P20839 1/20 0.41
CA2 P00918 4/20 0.39
CA1 P00915 2/20 0.39
CYP19A1 P11511 1/20 0.39
PTPRC P08575 1/20 0.38
PTPN6 P29350 1/20 0.38
PTPN11 Q06124 1/20 0.38
PTPN22 Q9Y2R2 1/20 0.38
DAPK3 O43293 1/20 0.37
MAP4K4 O95819 1/20 0.37
PRKACA P17612 1/20 0.37
LTK P29376 1/20 0.37
MAPK8 P45983 1/20 0.37
CSNK1A1 P48729 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29703081 1.00 SLC6A2 (0.49) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL28744575 0.94 SLC6A2 (0.46) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL9581565 0.89 SLC6A2 (0.43) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL27568557 0.85 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3CYP2A6IMPDH2
SCHEMBL506739 0.83 SLC6A2 (0.40) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
Benzothiophene SCHEMBL28779469 0.81 CA1 (0.42) SLC6A2SLC6A4SLC6A3CYP2A6IMPDH2
SCHEMBL9431320 0.79 CYP2A6 (0.46) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL97411 0.79 CYP2A6 (0.50) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL9581145 0.78 CTNNB1 (0.39) SLC6A2SLC6A4SLC6A3CYP2A6DYRK1A
SCHEMBL13563056 0.73 CA1 (0.36) SLC6A2SLC6A4SLC6A3CYP2A6IMPDH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 150 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3528813-B1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ABS DEV 1 INC (US) 2025-04-16 EP disclosed
WO-2024259241-A1 5-HT2A RECEPTOR MODULATORS AND METHODS OF USE THEREOF Transneural Therapeutics, Inc. (US) 2024-12-19 WO disclosed
US-20240391925-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS ASANA BIOSCIENCES, LLC (US) 2024-11-28 US disclosed
US-12077543-B2 P2X3 and/or P2X2/3 compounds and methods ASANA BIOSCIENCES, LLC (US) 2024-09-03 US disclosed
CN-114605378-B Thiophene condensed ring compound and synthetic method and application thereof 华中科技大学 2023-11-14 CN disclosed
CN-116854693-A P2X 3 And/or P2X 2/3 Compounds and methods 阿沙纳生物科学公司 2023-10-10 CN disclosed
CN-111491935-B Novel analogs as modulators of androgen and glucocorticoid receptors 昂科斯特拉公司 2023-08-22 CN disclosed
US-20230257355-A1 HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-08-17 US disclosed
US-20230257355-A1 HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF CHINA PHARMACEUTICAL UNIVERSITY (CN) 2023-08-17 US disclosed
CN-109996546-B P2X 3 And/or P2X 2/3 Compounds and methods 阿沙纳生物科学公司 2023-06-27 CN disclosed
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst MITSUBISHI RAYON CO., LTD. (JP) 2005-07-07 US disclosed
EP-1481978-A1 PROCESS FOR PRODUCTION OF HETEROARYL-TYPE BORON COMPOUNDS WITH IRIDIUM CATALYST Mitsubishi Rayon Co., Ltd. (JP) 2004-12-01 EP disclosed
EP-0355827-B1 Hydantoin derivatives MOCHIDA PHARM CO LTD (JP) 1997-01-02 EP disclosed
US-RE35279-E ALDOSE REDUCTASE INHIBITORS MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1996-06-18 US disclosed
US-5340833-A Antiarthritic, antiinflammatory, antitumor agents EISAI CO., LTD. (JP) 1994-08-23 US disclosed
EP-0568289-A2 Benzothiophenes and thienothiophenes and related compounds useful, for example, as urokinase inhibitors Eisai Co., Ltd. (JP) 1993-11-03 EP disclosed
US-5202339-A Hypoglycemic, hypolipedemic agents MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1993-04-13 US disclosed
US-5004751-A Antidiabetic agents; aldoe reductase inhibitors MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1991-04-02 US disclosed
WO-1990002126-A1 HYDANTOIN DERIVATIVES MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1990-03-08 WO disclosed
EP-0355827-A2 Hydantoin derivatives MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 1990-02-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050148775-A1 Process for production of heteroaryl-type boron compounds with iridium catalyst PIN4, IPO5, HLCS SLC6A2 1036/4885SLC6A4 2141/4885SLC6A3 947/4885
US-12077543-B2 P2X3 and/or P2X2/3 compounds and methods P2RX3, P2RX6, P2RX2 SLC6A2 2925/4885SLC6A4 2654/4885SLC6A3 1877/4885
US-20240391925-A1 P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS P2RX3, P2RX6, P2RX2 SLC6A2 2925/4885SLC6A4 2654/4885SLC6A3 1877/4885
US-20230257355-A1 HYDROXAMIC ACID-CONTAINING COMPOUND, AND PREPARATION METHOD AND USE THEREOF SI, SCD, SMPD1 SLC6A2 1894/4885SLC6A4 1787/4885SLC6A3 3515/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.